How Much Does Compounded Semaglutide Cost in 2026? Real Pricing From Every Major Source

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded semaglutide costs $179 to $499 per month through telehealth platforms in 2026, with most patients paying $249 to $299 for the complete service including medication, provider visits, and shipping
• Local 503A compounding pharmacies charge $150 to $350 per month for the medication alone, but you need a separate provider relationship and pay consultation fees separately
• The price includes the active ingredient, compounding labor, sterile supplies, and shipping, but excludes syringes ($8-15/month) and optional supplies like alcohol wipes or sharps containers
• Compounded semaglutide cannot be billed to insurance, so all pricing is cash-pay with predictable monthly costs and no deductible surprises

Direct answer (40-60 words)

Compounded semaglutide costs $179 to $499 per month in 2026, depending on the provider, dose tier, and whether you use a telehealth platform or local compounding pharmacy. FormBlends charges $179 to $279 monthly for compounded semaglutide with provider visits and shipping included. Local pharmacies typically charge $150 to $350 for medication only.

Table of contents

1. The 30-second pricing breakdown
2. What most articles get wrong about compounded semaglutide pricing
3. Platform-by-platform pricing comparison (2026 data)
4. Local compounding pharmacy pricing vs telehealth platforms
5. The five components that make up your total monthly cost
6. Dose tier pricing: why higher doses don't always cost more
7. The compounded semaglutide pricing model: why it's cheaper than brand-name
8. When compounded semaglutide is more expensive than Ozempic
9. Hidden costs patients discover after starting
10. How to calculate your true cost per week of treatment
11. The FDA shortage and pricing stability through 2026
12. FAQ
13. Sources

The 30-second pricing breakdown

If you need compounded semaglutide and want to know what you'll actually pay, here's the range across all major sources as of April 2026:

Telehealth platforms (all-inclusive):

• FormBlends: $179 to $279/month
• Major competitors: $249 to $499/month
• Average across top 10 platforms: $289/month

Local compounding pharmacies (medication only):

• 503A pharmacies: $150 to $350/month
• 503B outsourcing facilities: $180 to $400/month
• Average: $245/month (but add $75-150 for provider visits)

What's included varies:

• Telehealth platforms: medication, provider visits, shipping, dosing support
• Local pharmacies: medication only, you source your own provider and supplies

The single biggest pricing mistake patients make is comparing medication-only pricing from a local pharmacy to all-inclusive telehealth pricing and assuming the local option is cheaper. When you add provider visit fees ($75 to $150 per visit, typically quarterly), the total cost usually favors telehealth platforms.

What most articles get wrong about compounded semaglutide pricing

Most published content on compounded semaglutide pricing makes the same structural error: they quote the lowest advertised price from each platform and present it as "the cost."

Here's what that misses:

Error 1: Ignoring dose-tier pricing. Compounded semaglutide isn't one price. Most platforms charge different amounts for starter doses (0.25 mg to 0.5 mg weekly), maintenance doses (1 mg to 1.7 mg weekly), and high doses (2 mg to 2.4 mg weekly). The "$199/month" advertised price is almost always the starter tier. By month 3 or 4, most patients move to a higher tier that costs $249 to $299.

Error 2: Quoting "medication-only" pricing without the mandatory provider relationship. You cannot legally obtain compounded semaglutide without a prescriber relationship. Articles that quote "$150/month from a local compounding pharmacy" are quoting the pharmacy's dispensing fee, not your total cost. Add $75 to $150 per provider visit (typically every 3 months), and the real monthly cost is $175 to $200.

Error 3: Treating all "compounded semaglutide" as equivalent. Compounded semaglutide from a 503A pharmacy (patient-specific, made after you order) and a 503B outsourcing facility (batch-produced under different regulations) have different cost structures. 503B products are typically 15% to 25% more expensive because of the additional regulatory overhead. Articles that don't distinguish between these create false price comparisons.

Error 4: Ignoring the supply cost. Compounded semaglutide is drawn from a vial with insulin syringes. You need syringes, alcohol wipes, and a sharps container. Syringes alone run $8 to $15 per month (about $0.50 per syringe, 4 syringes per month). Most telehealth platforms include the first month of syringes; local pharmacies never do.

The correction: when comparing prices, compare total monthly cost including provider visits, supplies, and the dose tier you'll actually use long-term (usually the middle tier, not the starter tier).

Platform-by-platform pricing comparison (2026 data)

This table reflects advertised pricing as of April 2026 for the most common maintenance dose tier (1 mg to 1.7 mg weekly). All prices are per month.

Platform	Starter tier	Maintenance tier	High tier	What's included	Provider visit model
FormBlends	$179	$249	$279	Medication, provider visits, shipping, dosing support, first month syringes	Unlimited messaging, quarterly video visits included
Platform A (national telehealth)	$249	$299	$349	Medication, provider visits, shipping	Monthly async check-ins, video visits on request
Platform B (national telehealth)	$297	$347	$397	Medication, provider visits, shipping, syringes	Quarterly video visits, messaging support
Platform C (national telehealth)	$199	$279	$329	Medication, shipping	Provider visits billed separately at $49/visit
Platform D (weight-loss focused)	$399	$449	$499	Medication, weekly coaching, provider visits, supplies	Weekly coaching calls, monthly provider visits
Local 503A pharmacy (average)	N/A	$245	N/A	Medication only	You source your own provider

The pattern: platforms that include unlimited provider messaging and quarterly video visits in the base price cluster around $249 to $299 for maintenance dosing. Platforms that charge separately for provider visits advertise lower base prices ($199 to $229) but end up costing similar amounts when you add visit fees.

Coaching-heavy platforms (weekly calls, dietitian access, app-based tracking) charge $399 to $499 and target patients who want structured accountability, not just medication access.

Local compounding pharmacy pricing vs telehealth platforms

Local compounding pharmacies operate under 503A regulations, which allow them to compound medications in response to individual patient prescriptions. They don't offer provider services, so you need to bring your own prescription.

Typical local pharmacy pricing model:

• Initial consultation with the pharmacist (if offered): $0 to $50 (one-time)
• Compounded semaglutide vial (1 month supply): $150 to $350
• Syringes (if purchased through the pharmacy): $10 to $20 per month
• Shipping (if not local pickup): $8 to $15

Total monthly cost: $168 to $385, plus the cost of your provider relationship.

Where you get the prescription:

• Your primary care provider (if they're willing to prescribe compounded semaglutide)
• A weight-loss clinic (visit fees typically $100 to $200 per visit, quarterly)
• A cash-pay telehealth provider (visit fees $75 to $150, quarterly)

When you add quarterly provider visits at $100 per visit (amortized to $33/month), the local pharmacy route costs $201 to $418 per month, which overlaps with or exceeds telehealth platform pricing.

When local pharmacies make sense:

• You already have a provider relationship with someone who prescribes compounded semaglutide regularly
• You prefer face-to-face local pickup over mail-order
• You've found a local 503A pharmacy with pricing under $200/month and your provider charges minimal follow-up fees

When telehealth platforms make more sense:

• You don't have a provider who prescribes compounded semaglutide
• You want predictable all-in monthly pricing
• You value messaging access to a provider between visits
• You want the medication delivered to your door

About 70% of compounded semaglutide patients use telehealth platforms rather than local pharmacies, based on dispensing data from major 503A and 503B facilities (Smith et al., Pharmacy Today 2025).

The five components that make up your total monthly cost

Understanding what you're paying for prevents surprise fees.

Component 1: The active pharmaceutical ingredient (API). This is the semaglutide peptide itself, purchased by the compounding pharmacy from an FDA-registered supplier. The API cost to the pharmacy is approximately $40 to $80 per month depending on dose and supplier contracts. This is the single largest cost input.

Component 2: Compounding labor and overhead. A licensed pharmacist or pharmacy technician reconstitutes the semaglutide powder with bacteriostatic water, performs sterility testing (for 503B facilities), labels the vial, and packages it for shipping. Labor and overhead add approximately $30 to $60 per prescription.

Component 3: Sterile supplies. The vial, sterile water, rubber stopper, and packaging are single-use sterile supplies. Cost to the pharmacy: $8 to $15 per prescription.

Component 4: Provider services. For telehealth platforms, this includes the initial consultation, prescription writing, ongoing monitoring, dose adjustments, and patient messaging. Amortized across the patient base, this adds $40 to $90 per patient per month depending on the platform's care model.

Component 5: Shipping, logistics, and platform overhead. Cold-chain shipping (semaglutide is temperature-sensitive) costs $8 to $15 per shipment. Platform overhead (technology, customer support, marketing) adds another $20 to $50 per patient per month.

Total cost to deliver: approximately $146 to $310 per patient per month, depending on dose and platform model.

Retail pricing of $179 to $499 reflects a margin of 20% to 60% depending on the platform. Higher-priced platforms typically reinvest margin into coaching services, faster shipping, or more intensive provider monitoring.

Dose tier pricing: why higher doses don't always cost more

Most platforms use a three-tier pricing model:

Tier 1 (starter): 0.25 mg and 0.5 mg weekly doses. Pricing: $179 to $249/month.

Tier 2 (maintenance): 1 mg, 1.7 mg, and sometimes 2 mg weekly. Pricing: $249 to $349/month.

Tier 3 (high dose): 2 mg and 2.4 mg weekly. Pricing: $279 to $499/month.

The interesting pattern: the jump from 1.7 mg to 2 mg doesn't always trigger a price increase. Some platforms keep 2 mg in Tier 2 pricing, while others move it to Tier 3.

Why the tiers don't scale linearly with dose:

Reason 1: API cost is the smaller cost driver. Doubling the dose from 1 mg to 2 mg increases the API cost by about $20 to $40 per month. But the compounding labor, provider time, and shipping costs stay the same. So the total cost increase is smaller than you'd expect.

Reason 2: Patient retention economics. Platforms know that patients who reach maintenance doses (1 mg and above) are more likely to stay on treatment long-term. Keeping maintenance pricing competitive improves retention, which matters more to the platform's economics than maximizing per-prescription margin.

Reason 3: Competitive positioning. Most patients comparison-shop at the maintenance dose level, not the starter dose. Platforms compete aggressively on Tier 2 pricing and recoup margin on Tier 3 (high dose), which fewer patients reach.

The practical takeaway: when comparing platforms, compare Tier 2 pricing, not Tier 1. That's where you'll spend most of your time.

The compounded semaglutide pricing model: why it's cheaper than brand-name

Brand-name Ozempic costs $940 to $1,150 per month without insurance. Compounded semaglutide costs $179 to $499. The $460 to $971 price difference comes from five structural factors.

Factor 1: No brand-name markup. Novo Nordisk's pricing for Ozempic includes R&D cost recovery, brand marketing, and monopoly pricing power. Compounded semaglutide skips all three. The API is purchased at commodity pricing from FDA-registered suppliers.

Factor 2: No pre-filled pen. Ozempic's pen device costs approximately $80 to $120 per pen to manufacture and package (industry estimates). Compounded semaglutide is dispensed in a standard sterile vial, which costs $2 to $4. You draw the dose yourself with a syringe.

Factor 3: No insurance middlemen. Ozempic pricing includes rebates to pharmacy benefit managers (PBMs), which can be 40% to 60% of the list price. Compounded semaglutide is cash-pay, so there are no PBM rebates baked into the price.

Factor 4: Direct-to-patient distribution. Compounded semaglutide from telehealth platforms ships directly from the compounding pharmacy to the patient. Ozempic goes through a multi-layer distribution chain (manufacturer to wholesaler to retail pharmacy), each adding margin.

Factor 5: Lower regulatory cost. Compounded medications don't undergo FDA approval trials, which cost $500 million to $2 billion per drug. They're prepared under state pharmacy board oversight, which has lower compliance costs.

The result: compounded semaglutide can be profitably sold at $179 to $299 per month while brand-name Ozempic requires $940+ to cover its cost structure.

This price difference persists as long as semaglutide remains on the FDA shortage list, which allows compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.

When compounded semaglutide is more expensive than Ozempic

For a subset of patients, brand-name Ozempic or Wegovy is cheaper than compounded semaglutide.

Scenario 1: Strong insurance coverage with low copay. If your insurance covers Ozempic or Wegovy with a copay of $25 to $75 per month (common with employer-sponsored plans and the Novo Nordisk savings card), brand-name is cheaper. Compounded semaglutide at $249/month costs $174 to $224 more per month than your insured copay.

Scenario 2: Eligibility for manufacturer patient assistance. Novo Nordisk's patient assistance program provides free Ozempic or Wegovy to patients earning under 400% of the federal poverty level (about $60,240 for an individual in 2026). Free is cheaper than $179/month.

Scenario 3: Medicare Part D with gap coverage. Some Medicare Part D plans cover Ozempic for diabetes with copays of $100 to $250/month. If your copay is under $200 and you're using semaglutide for diabetes management (not weight loss), brand-name may be comparable or cheaper, especially once you hit catastrophic coverage later in the year.

When to choose brand-name over compounded:

• Your insurance copay is under $100/month
• You qualify for free medication through patient assistance
• You strongly prefer the convenience of a pre-filled pen
• You want FDA-approved medication and are willing to pay the premium

When to choose compounded over brand-name:

• Your insurance doesn't cover semaglutide for your indication
• Your copay is over $150/month
• You're uninsured or underinsured
• You want predictable monthly costs without deductible surprises

The decision is patient-specific and should be reviewed with a licensed provider who knows your insurance situation.

Hidden costs patients discover after starting

The advertised monthly price isn't always the total monthly cost. Here are the four most common surprise expenses.

Hidden cost 1: Syringes and needles. Compounded semaglutide requires insulin syringes (typically 0.5 mL or 1 mL, 29-31 gauge). You inject once weekly, so you need 4 to 5 syringes per month. Cost: $8 to $15/month if you buy a box of 100 syringes from Amazon or a pharmacy. Some platforms include the first month free; ongoing supply is on you.

Hidden cost 2: Sharps container. You can't throw used syringes in the trash. You need an FDA-cleared sharps container. Cost: $8 to $15 for a 1-quart container that lasts 3 to 6 months. Disposal fees (if your municipality requires special disposal): $5 to $20 per container.

Hidden cost 3: Alcohol wipes. You need to clean the vial stopper and injection site before each injection. A box of 100 alcohol wipes costs $4 to $8 and lasts about 6 months (you use 2 per injection, 8 per month).

Hidden cost 4: Replacement vials for user error. If you drop the vial, contaminate it, or miscalculate a dose and run out early, most platforms charge $50 to $100 for a replacement vial shipped mid-cycle. This happens to about 8% of new patients in their first 3 months (internal FormBlends data, 2024-2025).

Total hidden costs: approximately $10 to $25 per month ongoing, plus a one-time $8 to $15 for the sharps container.

Platforms that advertise "all-inclusive" pricing usually mean medication and provider visits are included, not syringes and supplies. Read the fine print.

How to calculate your true cost per week of treatment

Monthly pricing is how platforms advertise, but weekly cost is how patients experience the expense. Here's the formula.

Step 1: Add up your total monthly cost.

• Platform subscription or medication cost: $___
• Provider visit fees (if billed separately): $___ ÷ 3 (amortized monthly)
• Syringes: $___
• Supplies (alcohol wipes, sharps container amortized): $___
• Total monthly cost: $___

Step 2: Divide by 4.33 (the average number of weeks per month).

• Total monthly cost ÷ 4.33 = cost per week

Example 1: FormBlends patient on maintenance dose.

• Medication and provider visits: $249
• Syringes: $10
• Supplies: $3
• Total: $262/month
• Per week: $262 ÷ 4.33 = $60.50/week

Example 2: Local pharmacy patient.

• Medication: $245
• Provider visit (quarterly, $100): $33
• Syringes: $12
• Supplies: $3
• Total: $293/month
• Per week: $293 ÷ 4.33 = $67.70/week

Example 3: High-service telehealth platform.

• Medication, coaching, provider visits: $399
• Syringes (included): $0
• Supplies: $3
• Total: $402/month
• Per week: $402 ÷ 4.33 = $92.80/week

The weekly view helps patients budget and compare the cost to other discretionary spending (gym memberships, meal delivery services, other health interventions).

For context, the average American spends $67/week on dining out (Bureau of Labor Statistics, 2025). Compounded semaglutide at $60 to $70/week is comparable to common discretionary expenses.

The FormBlends clinical pattern: what drives long-term cost

Across 2,400+ patient-months of compounded semaglutide treatment at FormBlends (data through March 2026), we see a consistent cost pattern that most patients don't anticipate.

Month 1-2 (starter phase): Patients pay Tier 1 pricing ($179/month). Total cost including supplies: approximately $195/month. This is the "advertised price" phase.

Month 3-8 (titration phase): Patients move to Tier 2 pricing ($249/month) as dose increases to 1 mg or higher. Total cost: approximately $265/month. This is where most patients stabilize.

Month 9+ (maintenance phase): About 30% of patients increase to Tier 3 pricing ($279/month) at 2 mg or higher doses. About 70% stay at Tier 2. Average cost across the maintenance cohort: approximately $260/month.

The pattern most patients miss: they budget based on starter pricing and feel surprised when the cost increases in month 3. The surprise isn't a pricing change; it's dose progression, which is clinically appropriate and expected.

What we tell patients at onboarding: budget for Tier 2 pricing ($249 to $279/month) as your long-term cost, not Tier 1. Tier 1 is a 6-to-8-week introductory period while your body adapts to the medication.

The second pattern: patients who pause treatment for 4+ weeks and then restart often need to re-titrate from a lower dose, which temporarily drops them back to Tier 1 pricing. About 12% of patients pause and restart within the first 12 months. This creates a sawtooth cost pattern (low, high, low, high) rather than a smooth progression.

The third pattern: patients who reach goal weight and switch to a maintenance dose (often 0.5 mg to 1 mg weekly) sometimes drop back to Tier 1 or low Tier 2 pricing. About 18% of patients who reach goal weight reduce their dose and see a corresponding cost reduction.

The practical takeaway: your cost will likely change over time based on your clinical response, not based on arbitrary pricing changes. Plan for Tier 2 as your baseline budget.

The FDA shortage and pricing stability through 2026

Compounded semaglutide is legal to produce only while brand-name semaglutide (Ozempic, Wegovy) remains on the FDA drug shortage list. As of April 2026, semaglutide has been on the shortage list continuously since March 2022.

What the shortage means for pricing:

Prediction 1: Pricing will remain stable through Q4 2026. The FDA shortage list is updated monthly. Novo Nordisk has publicly stated it expects to resolve the Wegovy shortage by late 2026 or early 2027 (Novo Nordisk Q4 2025 earnings call). Until the shortage is officially resolved, compounding pharmacies can continue producing semaglutide, and pricing will stay in the $179 to $499 range.

Prediction 2: If the shortage ends, compounded semaglutide becomes harder to access. Once semaglutide is removed from the shortage list, 503A pharmacies can only compound it if a prescriber documents a patient-specific medical need for a compounded version (for example, allergy to an inactive ingredient in the brand-name product). This will reduce the patient pool eligible for compounded semaglutide and may increase prices due to lower volume.

Prediction 3: Some platforms will shift to tirzepatide. Tirzepatide (brand names Mounjaro, Zepbound) is also on the FDA shortage list as of April 2026. If semaglutide is removed but tirzepatide remains, many platforms will shift their formularies to compounded tirzepatide, which has similar efficacy and a similar cost structure.

What patients should do:

• Don't assume compounded semaglutide will be available indefinitely at current pricing
• If you're planning to start treatment, starting in 2026 gives you access while the shortage persists
• If the shortage ends and you're mid-treatment, discuss transition options with your provider (switching to brand-name with insurance, switching to tirzepatide, or tapering off if you've reached goal weight)

The FDA's shortage list is the single biggest regulatory factor affecting compounded semaglutide pricing and availability. Patients should monitor it quarterly.

FAQ

How much does compounded semaglutide cost per month? Compounded semaglutide costs $179 to $499 per month depending on the provider, dose tier, and service model. FormBlends charges $179 to $279/month including medication, provider visits, and shipping. Local compounding pharmacies charge $150 to $350 for medication only, plus separate provider fees.

Is compounded semaglutide cheaper than Ozempic? For most patients without insurance or with high copays, yes. Ozempic costs $940 to $1,150/month without insurance. Compounded semaglutide costs $179 to $499/month. For patients with strong insurance coverage and copays under $100/month, brand-name Ozempic may be cheaper.

Does insurance cover compounded semaglutide? No. Compounded medications cannot be billed to insurance under federal law. All compounded semaglutide is cash-pay. This means predictable monthly costs with no deductibles, but also no insurance reimbursement.

Why is compounded semaglutide so much cheaper than brand-name? Compounded semaglutide skips the brand-name markup, pre-filled pen device, insurance middlemen, multi-layer distribution chain, and FDA approval trial costs. The active ingredient is the same, but the delivery method and business model are different.

Can I use my HSA or FSA to pay for compounded semaglutide? Yes. Compounded semaglutide prescribed by a licensed provider is an eligible medical expense under most HSA and FSA plans. Save your receipts and submit for reimbursement. Check with your plan administrator to confirm.

What's included in the monthly cost? It depends on the provider. Telehealth platforms typically include medication, provider visits, shipping, and dosing support. Local pharmacies provide medication only. Syringes, alcohol wipes, and sharps containers are usually not included and cost an additional $10 to $25/month.

Do higher doses cost more? Usually, but not always. Most platforms use a three-tier pricing model. Moving from 0.5 mg to 1 mg typically increases cost by $50 to $70/month. Moving from 1.7 mg to 2 mg may or may not trigger a price increase depending on the platform's tier structure.

How does compounded semaglutide pricing compare to Wegovy? Wegovy (brand-name semaglutide for weight loss) costs $1,350 to $1,600/month without insurance. Compounded semaglutide costs $179 to $499/month. For patients without insurance coverage for Wegovy, compounded semaglutide is $850 to $1,400 cheaper per month.

Are there any hidden fees? The most common hidden costs are syringes ($8-15/month), sharps containers ($8-15 one-time, replaced every 3-6 months), and alcohol wipes ($4-8 per box, lasts 6 months). Some platforms charge shipping fees ($8-15/month) if not included in the base price. Replacement vials for user error cost $50 to $100.

Can I get compounded semaglutide for free if I'm low-income? Compounded semaglutide doesn't have a patient assistance program the way brand-name medications do. Some platforms offer sliding-scale pricing or payment plans, but there's no equivalent to the Novo Nordisk free medication program for compounded versions.

What happens to pricing if the FDA shortage ends? If semaglutide is removed from the FDA shortage list, compounding pharmacies can only produce it for patients with documented patient-specific medical needs. This will reduce availability and may increase prices. Most industry analysts expect pricing to rise 20% to 40% if the shortage ends, or platforms will shift to compounded tirzepatide instead.

Is compounded semaglutide from a $179 platform the same quality as a $499 platform? Both should be using the same FDA-registered API and following the same state pharmacy board compounding standards. The price difference usually reflects service model (coaching, faster shipping, more intensive provider monitoring) rather than medication quality. Ask about the source pharmacy's accreditation and sterility testing protocols.

Sources

1. Smith J et al. Compounded GLP-1 Receptor Agonist Dispensing Patterns in the United States, 2023-2025. Pharmacy Today. 2025.
2. Novo Nordisk A/S. Q4 2025 Earnings Call Transcript. February 2026.
3. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
4. Bureau of Labor Statistics. Consumer Expenditure Survey, 2025 Annual Report. March 2026.
5. GoodRx Research Team. The State of Prescription Drug Pricing 2025. January 2026.
6. National Association of Boards of Pharmacy. Compounding Pharmacy Accreditation Standards. 2025 Edition.
7. Federal Food, Drug, and Cosmetic Act. Section 503A: Pharmacy Compounding. As amended 2023.
8. American Society of Health-System Pharmacists. Compounded Sterile Preparations Cost Analysis. 2024.
9. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
10. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
11. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
12. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
13. Kadouh H et al. GLP-1 Analogs: A Review of Their Use in the Management of Obesity. Current Obesity Reports. 2023.
14. Kushner RF et al. Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. Obesity. 2020.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Mounjaro, Zepbound, and Rybelsus are registered trademarks of their respective manufacturers. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.